PROVE-Pre-Eclampsia Obstetric Adverse Events: Establishment of a Biobank and Database for Pre-Eclampsia

Lina Bergman1,2,3, Karl Bergman4, Eduard Langenegger3

  • 1Department of Women's and Children's Health, Uppsala University, 75309 Uppsala, Sweden.

Cells
|April 30, 2021
PubMed

Insights

This study establishes a pre-eclampsia biobank in South Africa to research severe disease. It collects samples and data to understand pathophysiology and predict complications.

Area of Science:

  • Obstetrics and Gynecology
  • Cardiovascular Research
  • Neurology

Background:

  • Pre-eclampsia is a major global cause of maternal and infant mortality, particularly in low-middle income countries.
  • Severe pre-eclampsia can lead to significant organ damage, impacting long-term health.
  • There is a critical need for research infrastructure to study this condition in high-incidence regions.

Purpose of the Study:

  • To establish a pre-eclampsia biobank in South Africa for comprehensive research.
  • To focus on phenotyping severe pre-eclampsia and its organ complications.
  • To facilitate research into pathophysiology, prediction, and potential therapeutic targets.

Main Methods:

  • Collection of biological specimens and detailed clinical data from women with pre-eclampsia and controls.
  • Inclusion of advanced biophysical examinations: brain MRI, cardiac MRI, transcranial Doppler, echocardiography, and cognitive tests.
  • Two-month follow-up via telephonic interviews to assess outcomes.

Main Results:

  • Establishment of a biobank and database for severe pre-eclampsia in a high-incidence, low-middle income country setting.
  • Integration of diverse data types including clinical, biological, and advanced imaging.
  • Foundation laid for future research into pre-eclampsia pathophysiology and complications.

Conclusions:

  • The biobank provides a crucial resource for studying severe pre-eclampsia in South Africa.
  • This initiative will enhance understanding of disease mechanisms and aid in predicting organ damage.
  • The data generated can inform future drug evaluation and discovery for pre-eclampsia.